Dr. Zhu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2015 - 2018
- Yale School of MedicineClass of 2015
Certifications & Licensure
- MN State Medical License 2018 - 2025
- CT State Medical License 2017 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award American Society of Clinical Oncology (ASCO), 2020
- Outstanding Hematology/Oncology Fellow Award Minnesota Society of Clinical Oncology (MSCO), 2020
Publications & Presentations
PubMed
- 6 citationsMicrofluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.Daheui Choi, Alan M Gonzalez-Suarez, Mihai G Dumbrava, Michael Medlyn, Jose M de Hoyos-Vega
Advanced Science. 2024-02-01 - 27 citationsPembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.Mojun Zhu, Chunhua Chen, Nathan R Foster, Christopher Hartley, Taofic Mounajjed
Clinical Cancer Research. 2022-07-15 - 36 citationsDefactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C Lockhart
Clinical Cancer Research. 2022-12-15
Press Mentions
- Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal CarcinomaNovember 25th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: